Tradestie Institutional Equity Comparison Engine

QNRX vs REVB โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

REVB Overall Edge

REVB Captures Institutional Edge (3โ€“0 Pillars ยท 4โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Revelation Biosciences, Inc. Common Stock (REVB) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, QNRX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus REVB at 0.9x Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, QNRX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against REVB sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner REVB
QNRX N/M vs REVB 0.9x Fwd P/E
Growth & Margin Winner REVB
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner REVB
1Y -82.5% vs +329.1% ยท 52W Pos 0% vs 75%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
QNRX NASDAQ
Quoin Pharmaceuticals, Ltd. American Depositary Shares
Pharmaceutical Preparations
$3.36
-5.64% 1D
Market Cap $17.1M
1M Return -15.81%
1Y Return -82.54%
Forward P/E N/M
Unified AI Score
47.1 / 100 HOLD
Tech 33.0 Fund 55.0 Flow 50.0 Mom 64.0
REVB NASDAQ
Revelation Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$3.69
-4.16% 1D
Market Cap $2.1M
1M Return +2.5%
1Y Return +329.07%
Forward P/E 0.9x
Unified AI Score
43.7 / 100 HOLD
Tech 38.0 Fund 24.0 Flow 50.0 Mom 36.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: QNRX -82.54% REVB +329.07% Spread: +411.61 pp (REVB Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
QNRX TTM Op. Margin: 0.0% REVB TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on QNRX vs REVB. Trailing 12-month operating profitability (QNRX 0.0% vs REVB 0.0%) and valuation multiples (QNRX N/M vs REVB 0.9x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: QNRX (3) vs REVB (4)
Institutional Metric QNRX REVB Criterion Row Winner
Market Capitalization Scale $17.1M $2.1M Larger Scale QNRX
Trailing P/E Ratio Valuation 8.1x 0.9x Lower Multiple REVB
Forward P/E Ratio Valuation N/M 0.9x Lower Multiple REVB
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -142.6% -133.4% Higher ROE REVB
52-Week Range Position Momentum 0% ($3โ€“$24) 75% ($0โ€“$5) Stronger Trend REVB
Beta / 30D Volatility Risk Regime 1.35ฮฒ ยท 72% Vol 2.90ฮฒ ยท 101% Vol Lower Realized Risk QNRX
Unified Institutional Score Composite Signal 47.1 / 100 (HOLD) 43.7 / 100 (HOLD) Higher Composite QNRX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full QNRX vs REVB Buy Guide
QNRX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live QNRX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
REVB UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live REVB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither QNRX nor REVB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.